Hematology Home >
- Faculty
Weijing SunAssociate Professor of Medicine at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
16 Penn Tower
3400 Spruce Street Philadelphia, PA 19104-4283
Office: 215-662-6319, 662-7964
Fax: 215-662-2432 Email: weijing.sun@uphs.upenn.edu
Education:
MD Shanghai Medical University (It has been merged with Fudan University recently), Shanghai, China, 1982. MS University of Nebraska, Lincoln, Nebraska, 1991.
Post-Graduate Training
Staff, Shanghai Medical University, Shanghai, China, 1983-1987. Graduate Student , University of Nebraska, School of Life Sciences, Lincoln, Nebraska, 1987-1991. Post-doctoral Researcher, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, 1991-1995. Intern in Medicine, Loyola University Medical Center, Maywood, Illinois, 1995-1996. Resident in Medicine, Loyola University Medical Center Maywood, Illinois, 1996-1998. Fellow in Hem/Onc, University of Pennsylvania, Philadelphia, Pennsylvania, 1998-2001.
Certifications
Permanent linkInternal Medicine Board Certification , 1998. Medical Oncology Board Certification, 2001. Description of Research ExpertiseClinical investigation of new drug development in cancer treatment/therapy.Description of Clinical ExpertiseNational and reginal expert in the treatment/therapy of GI cancers: esophageal, gastric, pancreatic, hepatic, biliary, colorectal, and neuoendocrin cancers...Commitee member of National Continue Medical Education. Selected PublicationsSun W, Whittington R, Gallagher M, O’Dwyer P, Giantonia B, Metz J, and Haller D. : Two Phase I Combined Modality Studies of Concurrent Radiotherapy (XRT) With Continuous Infusion 5-FU, Epirubicin and Cisplatin (ECF) or Irinotecan (EIF) for Locally Advanced Upper GI Adenocarcinoma. Oncology (Huntint) 15(4): 430-434, 2004.Vertonese ML, Stevenson JP, Sun W, Redlinger M, Algazy K, Giantonio B, Hahn S Vaughn D, Thorn C, Whitehead AS, Haller D, O’Dwyer PJ. : Phase I trial of UFT/leucovorin in patients with advanced cancer. Euro J Cancer 40(4): 508-14, 2004. Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantoio B, Zimmer R, Petros W, Stratford M, Chaplin D, Young SL, Schnall M, O’Dwyer PJ: Phase I trial of the antivascular agent combretastain A4 phosephate on a five-day schedule to patients with cancer: MRI evidence for altered tumor blood flow. J Clin Oncol 21: 4428-4438, 2003. Sun W, Theobald M, Hershock D, Haller DG. : A phase I combination trial of fixed-dose-rate gemcitabine and irinotecan in patients with advanced pancreatic and biliary cancer. Gastrointestinal Cancers Symposium 1: 107a (A132), 2004 Notes: poster presentation. Zac T, Sun, W. : Cancer of large bowel and hepatobiliary tract. Cancer Chemotherapy & Biological Response Modifiers. Giaccone, Schilsky and Sondi eds, (eds.). Annual 22: 443-470, 2005. Sun W, Stevenson JP, Gallagher M, Vaughn D, Hahn SM, Haller DG, Gallant G, and O’Dwyer PJ. : Phase I and pharmacokinetic trial of BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. Clin Cancer Res 9(14): 5221-5227, 2003. Sun W., Rustgi AK. : Esophageal Neoplasms. Textbook of Gastroenterology, 4th ed. Tadataka Yamada (eds.). Lippincott Williams & Wilkins, Page: 24 (1238-1261), 2003. Sun, W., Haller D.: Cancer of large bowel and hepatobiliary tract. Cancer Chemotherapy & Biological Response Modifiers. Annual 21. Giaccone, Schilsky and Sondi (eds.). In Press 2003. d’Entremont TC, Sun, W. : Recent advances in colorectal cancer therapy. Cancer Biology & Therapy 2(1): 6-13, 2003. Sun, W., and Haller D.: Gastrointestinal Cancer. WebMD Scientific American of Medicine, ACP Medicine. A Publication of the American College of Physicians. David C. Dale, Daniel D. Federman (eds.). WebMD Scientific American of Medicine, 2004-2005 Edition: 2423-2444, 2004.
|
